Rationale and design of a randomized double blind parallel group study of terutroban 30 mg day versus aspirin 100 mg day in stroke patients the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack PERFORM study